Abliva AB (publ) (OTCMKTS:NEVPF) vs. Zymeworks (NYSE:ZYME) Head to Head Contrast

Zymeworks (NYSE:ZYME) and Abliva AB (publ) (OTCMKTS:NEVPF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Zymeworks and Abliva AB (publ), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0	0	11	0	3.00
Abliva AB (publ)	0	0	0	0	0.00

Zymeworks currently has a consensus price target of $32.82, indicating a potential upside of 23.28%. Given Zymeworks’ stronger consensus rating and higher probable upside, research analysts plainly believe Zymeworks is more favorable than Abliva AB (publ).

Profitability

This table compares Zymeworks and Abliva AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Abliva AB (publ)	N/A	-117.92%	-102.44%

Institutional and Insider Ownership

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zymeworks and Abliva AB (publ)”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$134.48 million	14.81	-$118.67 million	($0.84)	-31.69
Abliva AB (publ)	$10,000.00	1,128.43	-$9.01 million	N/A	N/A

Abliva AB (publ) has lower revenue, but higher earnings than Zymeworks.

Risk and Volatility

Zymeworks has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Abliva AB (publ) has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.

Summary

Zymeworks beats Abliva AB (publ) on 9 of the 12 factors compared between the two stocks.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

About Abliva AB (publ)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.